New Zealand - English - Medsafe (Medicines Safety Authority)

csl behring (nz) ltd - tetanus immunoglobulin, human 250 [iu] (immunoglobulin ex nz =160mg/ml) - solution for injection - 250 iu - active: tetanus immunoglobulin, human 250 [iu] (immunoglobulin ex nz =160mg/ml) excipient: glycine - tetanus immunoglobulin-vf is indicated for the passive protection of individuals who have sustained a tetanus-prone wound and who have either not been actively immunised against tetanus or whose immunisation history is doubtful. it should also be given to the fully immunised patient with a tetanus-prone wound if more than 10 years have elapsed since the last vaccine dose. in all the above instances, active immunisation with a tetanus vaccine should be commenced at the same time according to current datasheet recommendations.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - tetanus immunoglobulin, quantity: 250 iu; human immunoglobulin g, quantity: 160 mg/ml - injection, solution - excipient ingredients: glycine; human immunoglobulin a - tetanus immunoglobulin is indicated for the passive protection of individuals who have sustained a tetanus-prone wound and who have either not been actively immunised against tetanus or whose immunisation history is doubtful. it should also be given to the fully immunised patient with a tetanus-prone wound if more than 10 years have elapsed since the last dose of toxoid. in all the above instances, active immunisation with tetanus toxoid, adsorbed or adt vaccine should be commenced at the same time [in accordance with details specified in table 1 (guide to tetanus prophylaxis in wound management) in indication section of the approved product information provided as attachment 1]. although tetanus immunoglobulin and vaccine should be given at the same time, they should be administered in opposite limbs, using separate syringes.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - tetanus immunoglobulin, quantity: 4000 iu; human immunoglobulin g, quantity: 50 mg/ml - injection, intravenous infusion - excipient ingredients: maltose; water for injections; human immunoglobulin a - tetanus immunoglobulin-vf (for intravenous use) is used in the management of clinical tetanus.

Kenya - English - Pharmacy and Poisons Board

serum institute of india ltd. 212/2 hadapsar pune 411028 india - tetanus vaccine adsorbed - suspension for injection - each single 0.5 ml human dose contains tetanus… - bacterial vaccines: tetanus vaccines

Canada - English - Health Canada

id biomedical corporation of quebec - tetanus toxoid adsorbed - suspension - 5lf - tetanus toxoid adsorbed 5lf - toxoids

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - tetanus toxoid - suspension for injection - tetanus toxoid 40 iu - vaccines

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - tetanus toxoid - suspension for injection in pre-filled syringe - tetanus toxoid - vaccines

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - tetanus toxoid, quantity: 40 iu/ml; diphtheria toxoid, quantity: 4 iu/ml - injection, suspension - excipient ingredients: water for injections; sodium chloride; aluminium hydroxide hydrate; sodium hydroxide - vaccination of children (greater than or equal to 5 years of age) and adults who have previously received at least 3 doses of a vaccine for primary immunisation against diphtheria and tetanus. adt booster is not intended for primary immunisation against diphtheria and tetanus. use of adt booster should be scheduled in accordance with official national recommendations.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bio products laboratory ltd - tetanus immunoglobulin human - solution for injection - 250unit

Israel - English - Ministry of Health

padagis israel agencies ltd, israel - tetanus immune globulin (s/d treated) - solution for injection - tetanus immune globulin (s/d treated) 250 u/ml - tetanus immunoglobulin - tetanus immunoglobulin - immunity against tetanus toxin. treatment of active cases of tetanus.